Search

for
Search:

Glossary Infliximab

blocks TNF-alpha to reduce inflammation in autoimmune diseases

Infliximab, also known by the brand name Remicade, is a medication that works by blocking a protein called tumor necrosis factor-alpha (TNF-alpha). This protein is involved in inflammatory processes in the body. By inhibiting TNF-alpha, infliximab helps reduce inflammation and is used to treat autoimmune conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis.

Related Terms

Sort by

Research

30 / 567 results

Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn’s Disease: Dramatic Improvement After Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies

research Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn’s Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies

19 citations , November 2016 in “Dermatology and therapy”

This study describes a case where stopping infliximab and using oral minocycline with topical treatments effectively resolved alopecia and scalp psoriasis in a woman with Crohn's disease.

research Infliximab as First‐Line Therapy in Severe Pediatric Crohn Disease

19 citations , September 2006 in “Journal of Pediatric Gastroenterology and Nutrition”

In this case study, a 12-year-old girl with severe Crohn colitis achieved impressive clinical and endoscopic remission after receiving infliximab and azathioprine as first-line treatment, suggesting potential benefits of early intensive therapy.

research Cutaneous Crohn's disease treated with infliximab and 4 years of follow up

9 citations , June 2013 in “Australasian Journal of Dermatology”

This case study reports on an adult with metastatic Crohn's disease treated with infliximab over 4.5 years, providing valuable follow-up data in this context.

research Alopecia areata in a patient receiving infliximab

9 citations , January 2013 in “Indian journal of dermatology, venereology, and leprology”

Infliximab may cause hair loss in Crohn's disease patients.

research Hyperammonemia with Valproic Acid: Colonic Ischemia Associated with “Triptan” Use Visual Side Effects with Pegylated Interferon: Alopecia Areata with Infliximab: Adverse Effects Seen with Medications Used for Irritable Bowel Syndrome

2 citations , November 2004 in “Hospital pharmacy”

This article reviews adverse drug reactions, emphasizes methods of prevention, and encourages reporting to the FDA's medWatch program, but presents no new study findings.

research Infliximab-Associated Psoriasiform Alopecia

1 citations , October 2015 in “The American journal of gastroenterology”

This study reported two cases where infliximab-associated psoriasiform alopecia resolved with significant hair regrowth after stopping infliximab and using potent topical steroid treatment.

research Infliximab Induced Lupus in Crohnʼs Disease

1 citations , October 2013 in “The American Journal of Gastroenterology”

This case report documents a 59-year-old woman who developed atypical drug-induced lupus after receiving infliximab for Crohn's disease, with symptoms persisting even after discontinuation.

research S4890 Infliximab-Induced Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis Syndrome

October 2025 in “The American Journal of Gastroenterology”

This report describes a case of SAPHO syndrome likely triggered by escalated dosing of infliximab in a 21-year-old woman, highlighting the complex nature of infliximab-induced adverse events, and suggesting a potential autoimmune basis involving two distinct pathophysiologies for SAPHO syndrome.

research Successful treatment of refractory alopecia universalis with infliximab: First case report in Sri Lanka

December 2017 in “The Sri Lanka Journal of Dermatology”

This study reports a case where treatment with the TNF alpha inhibitor infliximab successfully resolved refractory alopecia universalis in a 41-year-old woman.

research Dissecting cellulitis of the scalp successfully treated with infliximab

April 2012

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

research Local infusion of infliximab for the treatment of acute joint inflammation

51 citations , July 2003 in “Annals of the Rheumatic Diseases”

This case study reports a successful use of co-trimoxazole in treating a 13-year-old girl with symptoms suggestive of autoimmune disorders and relapsing polychondritis.

Baseline Methotrexate Does Not Impact the Incidence of Infliximab Infusion Reactions: Results from a Canadian Real-World Treatment Registry

research Baseline methotrexate does not impact the incidence of infliximab infusion reactions: Results from a Canadian real-world treatment registry

April 2012 in “Journal of the American Academy of Dermatology”

In this survey of dermatologists, pimozide was most commonly identified as the preferred first-line antipsychotic for treating delusions of parasitosis, followed by risperidone.

research North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

256 citations , March 2019 in “Journal of the American Academy of Dermatology”

This review provides graded evidence and a therapeutic algorithm for managing hidradenitis suppurativa, but does not present new clinical results.

research Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas

104 citations , August 2008 in “Clinics in Dermatology”

This review discusses current treatment challenges and strategies for managing psoriasis in the scalp, nails, and intertriginous areas, emphasizing the need for effective and well-tolerated long-term options, but reports no new clinical results.

research Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients

90 citations , April 2013 in “Dermatology online journal”

This article reviews various medical treatments for hidradenitis suppurativa based on the author's experience with over 350 patients, but it reports no new clinical findings.

research Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis

78 citations , January 2013 in “Dermatology Online Journal”

This review discusses various diseases associated with hidradenitis suppurativa, including obesity, arthritis, and pyoderma gangrenosum, but reports no new clinical results and calls for further research.

research Safety of dermatologic medications in pregnancy and lactation

73 citations , March 2014 in “Journal of The American Academy of Dermatology”

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

research Interventions for nail psoriasis

65 citations , January 2013 in “Cochrane library”

This review found that infliximab, golimumab, and some forms of radiotherapy significantly improved nail psoriasis compared to controls, although they could have serious adverse effects and are not commonly used specifically for nail issues.

Drugs and Hair Loss: Mechanisms and Clinical Implications

research Drugs and Hair Loss

54 citations , September 2012 in “Dermatologic Clinics”

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

research An Update on Medical Treatment Options for Hidradenitis Suppurativa

36 citations , December 2015 in “Drugs”

This review summarizes various drug treatments for hidradenitis suppurativa, noting their effectiveness, side effects, and high recurrence rates, but reports no new clinical findings.

Comprehensive Overview of Hidradenitis Suppurativa

research Hidradenitis Suppurativa

27 citations , December 2015 in “Mayo Clinic Proceedings”

This review presents an evidence-based algorithm for managing hidradenitis suppurativa in primary care, highlighting the need for more research on treatment effectiveness and the disease's pathogenesis.

Alopecia Induced by Tumor Necrosis Factor-Alpha Antagonists: Description of 52 Cases and Disproportionality Analysis in a Nationwide Pharmacovigilance Database

research Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database

26 citations , March 2014 in “Rheumatology”

This study confirms an association between TNF-α antagonist exposure and alopecia, indicating a class effect among the medications examined.

research Tumor necrosis factor-induced alopecia: alternative pathology and therapy

7 citations , January 2017 in “Dermatology Online Journal”

In this case report, the researchers described two women with Crohn disease who developed alopecia related to TNF inhibitor therapy, noting various histopathological features of drug-induced alopecia and treating it effectively with different therapeutic approaches.

research Alopecia areata in a patient with psoriatic arthritis and Crohn's disease receiving etanercept

7 citations , April 2013 in “International Journal of Rheumatic Diseases”

This case report highlights a potential association between etanercept, a TNF-α blocker, and the onset of alopecia areata, suggesting complex interactions between anti-TNF-α treatments and hair follicle growth.

research TNF-α Inhibitor-Induced Psoriasis and Psoriatic Alopecia in Adolescent with Ulcerative Colitis: Clinical Case

3 citations , November 2023 in “Вопросы современной педиатрии”

This case study described a 17-year-old with paradoxical psoriasis and ulcerative colitis, triggered by TNF-α inhibitor therapy, who experienced clinical improvement and hair regrowth after switching to ustekinumab, which the authors note aligns with existing data on its effectiveness for these conditions.

research Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events

2 citations , April 2025 in “Biologics”

This study reviewed clinical trials and reports on cytokine-targeting biologics for alopecia areata, finding Dupilumab and Ustekinumab showed strong efficacy, while other biologics had limited success or worsened the condition. Further research is needed to optimize biologic therapies for AA.

research Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib

2 citations , September 2024 in “Internal Medicine Journal”

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

research Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis

1 citations , September 2025 in “Eye”

This pharmacovigilance study found that certain systemic medications, including finasteride, bortezomib, and dupilumab, were disproportionately reported in association with eyelid disorders like blepharitis, meibomian gland dysfunction, and chalazia, suggesting these drugs may contribute to these conditions though benefits might still outweigh the risks.

research S3909 Paradoxical Psoriasis and Alopecia Areata After the Use of Anti-TNF in a Patient With Crohn's Cisease

1 citations , October 2024 in “The American Journal of Gastroenterology”

In this case report, a patient with Crohn's disease experienced alopecia and psoriasiform reactions attributed to anti-TNF therapy, which improved after switching to Ustekinumab.

research Current systemic treatment strategies for hidradenitis suppurativa

1 citations , January 2017 in “Expert opinion on orphan drugs”

This study reviews current systemic treatments for hidradenitis suppurativa, highlighting traditional methods and new options like biological agents, and suggests that pharmacological therapies show promise, particularly for non-advanced cases, despite the disease's complex etiology involving factors such as genetics and inflammation.